Circulating expression levels of CircHIPK3 and CDR1as circular-RNAs in type 2 diabetes patients

Mol Biol Rep. 2022 Jan;49(1):131-138. doi: 10.1007/s11033-021-06850-8. Epub 2021 Nov 3.

Abstract

Background: Recent investigations suggested that deregulated levels of Circular RNAs (circRNAs) could be associated with type 2 diabetes mellitus (T2DM) pathogenesis. Accordingly, this study aimed to determine the expression levels of circulating CircHIPK3, CDR1as and their correlation with biochemical parameters in patients with T2DM, pre-diabetes and control subjects.

Methods and results: The expression of circRNAs in peripheral blood was determined using QRT-PCR in 70 patients with T2DM, 60 pre-diabetes and in 69 age and sex matched healthy controls. Moreover, bioinformatics tools were applied to explore and predict the potential interactions between circRNAs and other non-coding RNAs (ncRNAs). Our analysis revealed that the expression level of CircHIPK3 was significantly elevated in T2DM patients compared to healthy participants (P < 0.001) and pre-diabetes subjects (P = 0.018). In addition, ROC analysis suggested that at the cutoff value of 0.24 and the sensitivity and specificity of 50% and 88.4%, respectively, CircHIPK3 could distinguish between T2DM patients and control subjects. Furthermore, it was observed that the expression level of CDR1as is higher in pre-diabetic individuals than healthy individuals (P = 0.004). Finally, Spearman correlation analysis showed that there was a significant correlation between CircHIPK3 and CDR1as expression levels and clinical and anthropometrical parameters such as BMI, systolic and diastolic blood pressure, HbA1c and fasting blood glucose (P < 0.005).

Conclusions: The data of this study provided evidence that the expression levels of CircHIPK3, CDR1as increased in T2DM and pre-diabetes subjects, respectively.

Keywords: CDR1as; CircHIPK3; Circular RNA; Type 2 diabetes mellitus.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / genetics
  • Diagnosis, Differential
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prediabetic State / blood
  • Prediabetic State / diagnosis*
  • Prediabetic State / genetics
  • RNA, Circular / blood*
  • RNA, Long Noncoding / blood*
  • ROC Curve
  • Sensitivity and Specificity
  • Up-Regulation

Substances

  • RNA, Circular
  • RNA, Long Noncoding
  • long non-coding RNA CDR1AS, human